Downloaded from http://spcare.bmj.com/ on September 22, 2015 - Published by group.bmj.com
Feature
Opioids in palliative care: is the new NICE guideline relevant to specialist palliative care providers? Mark Taubert,1–3 Joy R Ross,4,5 Matthew Prettyjohns,6 Mia Schmidt-Hansen,6 Michael I Bennett7 1Department
of Palliative Medicine, Marie Curie Hospice Penarth, Penarth, UK 2University Hospital Llandough, Penarth, UK 3Velindre Hospital NHS Trust, Cardiff, UK 4 Department of Palliative Medicine, Royal Marsden NHS Foundation Trust, London, UK 5NHLI, Imperial College, London, UK 6National Collaborating Centre for Cancer, Cardiff CF10 3AF, UK 7Leeds Institute of Life Sciences, Leeds University, Leeds, UK Correspondence to Dr Mark Taubert, Department of Palliative Medicine, Marie Curie Hospice Penarth, Bridgeman Road, Penarth, Cardiff CF64 3YR, UK; [email protected] Received 29 June 2012 Accepted 29 June 2012 Published Online First 30 July 2012
INTRODUCTION The National Institute for Health and Clinical Excellence (NICE) issued guideline CG140 in May 2012, for professionals commencing strong opioids in adult palliative care patients.1 Although this guideline is for non-specialist professionals who initiate opioid treatment (eg, general practitioners and generalist hospital doctors), the implications for those working in specialist palliative care settings will be significant. It is important that NICE guidelines should facilitate and consolidate the ongoing dialogue between generalists and specialists in palliative care. Here, we summarise the recommendations to highlight areas that are of particular importance to specialist palliative care providers.
standard baseline of care (table 1). While the prescriber is responsible for ensuring that this patient– professional dialogue occurs, it may be the case that other healthcare professionals (nurses, pharmacists) will engage and/or expand on these conversations. Given the limited research to date in this area, a research recommendation was agreed upon to explore this further: What are the most clinically effective and costeffective methods of addressing patient and carer concerns about strong opioids, including anticipating and managing adverse effects and engaging patients in prescribing decisions? (Research Recommendation B13).
STARTING STRONG OPIOIDS BACKGROUND Development of this guideline followed the NICE process for short clinical guideline development. 2 Recommendations within the guideline were made after systematic reviews had been conducted to consider the best available evidence. Where minimal evidence was available, the Guideline Development Group’s experience and opinion of what constitutes good practice was debated, considered and summarised. The guideline takes effect at the point in time when a palliative care patient has moderate to severe pain, which necessitates commencing strong opioid analgesia. The guideline does not cover the last days of life, nor does it go further into recommendations for second-line approaches for pain control. A number of key areas are addressed: communication, starting strong opioids (fi rst-line treatment options, titrating the dose, maintenance phase and what to do when oral opioids are not suitable), management of breakthrough pain, and management of side effects (constipation, nausea and drowsiness). These are summarised in table 1.
COMMUNICATION The Guideline Development Group (GDG) highlighted that communication with patients starting opioids is often inadequate and should incorporate the salient aspects of what opioid therapy entails. GDG members working in both community and hospital settings were aware that communication gaps exist when this intervention (initiation of opioids) is made. Exploring patients’ concerns when discussing an opioid for the fi rst time has a significant impact on whether or not a patient actually takes their medication as prescribed. The GDG recommended a minimum level of information that should be covered to constitute a good BMJ Supportive & Palliative Care 2012;2:209–212. doi:10.1136/bmjspcare-2012-000313
Titrating the dose: the guideline is focused on the decision to commence strong opioids. This decision might be made by a general practitioner reviewing a community palliative care patient or a hospital doctor seeing an inpatient on a ward. The GDG agreed that offering patients a choice of immediate- or sustained-release formulations would be likely to improve adherence because patients would be able to choose the formulation that was most acceptable to them. Based on their clinical experience, the GDG recommended that all patients are given rescue doses of an immediate-release opioid to be taken as required, in order to minimise pain in the initial titration phase. Wide ranges of doses are used in the initiation of opioids by hospital and community practitioners, and the guideline literature varies considerably.4 While NICE guidelines would not usually recommend doses, feedback from the consultation process and the GDG was that this was an important safety consideration. It was therefore decided that a safe starting dose of morphine should be suggested, to give inexperienced practitioners faced with a prescribing decision clearer guidance. The GDG recommended a starting dose of regular oral daily opioid (which can be prescribed as a regular immediate-release or sustained-release preparation) of 20–30 mg of morphine over 24 h, plus additional rescue doses of immediate-release oral morphine at a dose of 5 mg. It was also agreed that in both inpatient and community settings, regular and frequent review was necessary in the titration phase to allow appropriate dose escalation to achieve analgesia and to monitor side effects. For those patients with renal or hepatic impairment, specialist advice from a palliative care team should be sought, due to the challenges these particular clinical situations can pose when prescribing opioids. 209
Downloaded from http://spcare.bmj.com/ on September 22, 2015 - Published by group.bmj.com
Feature Table 1
Summary of NICE recommendations for opioids in palliative care
Communication 1.1.1 When offering pain treatment with strong opioids to a patient with advanced and progressive disease, ask them about concerns such as: addiction, tolerance, side effects, fears that treatment implies the final stages of life. 1.1.2 Provide verbal and written information on strong opioid treatment to patients and carers, including the following: when and why strong opioids are used to treat pain; how effective they are likely to be; taking strong opioids for background and breakthrough pain; addressing how, when and how often to take strong opioids, and how long pain relief should last; side effects and signs of toxicity; safe storage; follow-up and further prescribing; information on who to contact out of hours, particularly during initiation of treatment. 1.1.3 Offer patients access to frequent review of pain control and side effects. Starting strong opioids – titrating the dose 1.1.4 When starting treatment with strong opioids, offer patients with advanced and progressive disease regular oral sustained-release or oral immediate-release morphine (depending on patient preference), with rescue doses of oral immediate-release morphine for breakthrough pain. 1.1.5 For patients with no renal or hepatic comorbidities, offer a typical total daily starting dose schedule of 20–30 mg of oral morphine (for example, 10–15 mg oral sustained-release morphine twice daily), plus 5 mg oral immediate-release morphine for rescue doses during the titration phase. 1.1.6 Adjust the dose until a good balance exists between acceptable pain control and side effects. If this balance is not reached after a few dose adjustments, seek specialist advice. Offer patients frequent review, particularly in the titration phase. 1.1.7 Seek specialist advice before prescribing strong opioids for patients with moderate to severe renal or hepatic impairment. First-line maintenance treatment 1.1.8 Offer oral sustained-release morphine as first-line maintenance treatment to patients with advanced and progressive disease who require strong opioids. 1.1.9 Do not routinely offer transdermal patch formulations as first-line maintenance treatment to patients in whom oral opioids are suitable. 1.1.10 If pain remains inadequately controlled despite optimising first-line maintenance treatment, review analgesic strategy and consider seeking specialist advice. First-line treatment if oral opioids are not suitable – transdermal patches 1.1.11 Consider initiating transdermal patches with the lowest acquisition cost for patients in whom oral opioids are not suitable and analgesic requirements are stable, supported by specialist advice where needed. 1.1.12 Use caution when calculating opioid equivalence for transdermal patches: a transdermal fentanyl 12 µg patch equates to approximately 45 mg oral morphine daily. A transdermal buprenorphine 20 µg patch equates to approximately 30 mg oral morphine daily. First-line treatment if oral opioids are not suitable – subcutaneous delivery 1.1.13 Consider initiating subcutaneous opioids with the lowest acquisition cost for patients in whom oral opioids are not suitable and analgesic requirements are unstable, supported by specialist advice where needed. First-line treatment for breakthrough pain in patients who can take oral opioids 1.1.14 Offer oral immediate-release morphine for the first-line rescue medication of breakthrough pain in patients on maintenance oral morphine treatment. 1.1.15 Do not offer fast-acting fentanyl as first-line rescue medication. 1.1.16 If pain remains inadequately controlled despite optimising treatment, consider seeking specialist advice. Management of constipation 1.1.17 Inform patients that constipation affects nearly all patients receiving strong opioid treatment. 1.1.18 Prescribe laxative treatment (to be taken regularly at an effective dose) for all patients initiating strong opioids. 1.1.19 Inform patients that treatment for constipation takes time to work, and adherence is important. 1.1.20 Optimise laxative treatment for managing constipation before considering switching strong opioids. Management of nausea 1.1.21 Advise patients that nausea may occur when starting strong opioid treatment or at dose increase, but that it is likely to be transient. 1.1.22 If nausea persists, prescribe and optimise antiemetic treatment before considering switching strong opioids. Management of drowsiness 1.1.23 Advise patients that mild drowsiness or impaired concentration may occur when starting strong opioid treatment or at dose increase, but that it is often transient. Warn patients that impaired concentration may affect their ability to drive and undertake other manual tasks. 1.1.24 In patients with either persistent or moderate to severe central nervous system side effects: consider dose reduction if pain is controlled, or consider switching opioids if pain is not controlled. 1.1.25 If side effects remain uncontrolled despite optimising treatment, consider seeking specialist advice.
FIRST-LINE MAINTENANCE TREATMENT A literature search and a health economic modelling exercise 5 were conducted to establish the most effective fi rst-line maintenance treatment for patients with advanced and progressive disease who are able to take oral opioids. The GDG noted that uncertainty exists over the choice of a strong opioid for the maintenance treatment of background pain. The prescription of transdermal fentanyl and buprenorphine preparations has increased in both hospital and community settings, and the GDG decided that this warranted further consideration. Based on the available evidence, the GDG noted that morphine is an effective and inexpensive opioid analgesic. Although its use may result in a small increase in gastrointestinal side effects compared with transdermal patches, the 210
GDG agreed that this could be managed by using adjunctive treatment. More costly preparations would need to be justified by evidence of superior efficacy or a much lower sideeffect burden. Studies comparing the effectiveness of fentanyl, buprenorphine and oxycodone with morphine were of poor quality and did not demonstrate superiority over morphine. Health economic modelling showed that the benefit potentially conferred by fentanyl in reducing gastrointestinal side effects was not shown to be cost effective (ICER £107 532 per quality adjusted life year (QALY) gained at 1 month, see table 2 for explanation of abbreviations. The threshold that NICE sets for QALYs is £20 000 per QALY). It was agreed that oral sustained-release morphine should be recommended as fi rst-line maintenance treatment for patients BMJ Supportive & Palliative Care 2012;2:209–212. doi:10.1136/bmjspcare-2012-000313
Downloaded from http://spcare.bmj.com/ on September 22, 2015 - Published by group.bmj.com
Feature Table 2
Definitions of CEA, ICER and QALY8
NICE is charged with considering both the effectiveness and cost effectiveness of treatments, and then with making recommendations as to their provision within the National Health Service (NHS). QALY: the QALY is based on the number of years of life that may be added by an intervention. Each year in ‘full or perfect health’ is assigned the value of 1.0, and this can go down to a value of 0.0 for death. If the extra years cannot be lived in full health, for instance, if a patient were to be restricted in their mobility or in severe pain, then the extra life years are given a value between 0 and 1 to take this debility into account. CEA: assesses two or more alternative courses of action in terms of their costs and benefi ts. The comparison is summarised using the expected ICER. ICER: this is a measure of the additional cost per additional unit of health gain produced by one intervention compared with another. The Institute’s preferred form of cost effectiveness analysis uses the QALY to describe the outcome of each intervention. By extension, the Institute’s preferred form of ICER is the cost per QALY gained. The cost-effectiveness threshold is often referred to as society’s willingness to pay for an additional unit of health gain (QALY); that is, if the ICER for a specific intervention is less than the cost-effectiveness threshold, then society, or its agents, will be willing to fund it, and conversely, if the ICER is greater than the threshold, society will not be willing to fund it. CEA, cost-effectiveness analysis; ICER, incremental cost-effectiveness ratio; NICE, National Institute for Health and Clinical Excellence; QALY, quality adjusted life year.
Table 3 Therapy
Costs of breakthrough pain medication Average price per Regular dose Breakthrough dose (a) breakthrough event (£)
Morphine 60 mg Oxycodone 30 mg Fentanyl 25 µg/h (b) Intranasal (c) Sublingual Buccal Buccal
10 mg 5 mg
0.09 0.20
100 µg 100 µg 100 µg (d) 200 µg (e)
4.88 4.99 4.99 5.85
a Typically one-sixth of regular daily dose. b Patch dose. c Average of instanyl (100 µg) and pecfent (100 µg). d Initial dose of effentora (100 µg). e Initial doses of actiq (200 µg).
with advanced disease, and that transdermal patch formulations should not be used routinely as fi rst-line treatment. If pain control remains inadequate despite titrating and optimising oral sustained-release morphine, then generalist prescribers should consider seeking specialist palliative care advice.
FIRST-LINE TREATMENT IF ORAL OPIOIDS ARE NOT SUITABLE – TRANSDERMAL PATCHES AND SUBCUTANEOUS DELIVERY The GDG addressed the question of what happens to patients who cannot swallow oral medication, or have impaired absorption from the gastrointestinal tract (eg, due to nausea and vomiting). Recommendations were made on the use of transdermal and subcutaneous routes of administration in this setting. The evidence for effectiveness of transdermal patches was low quality, and defi nitive recommendations on which transdermal patch to offer patients could not be made. The GDG recognised that most patients in this category would have complex medical needs requiring specialist advice, however, there needed to be flexibility for experienced generalist prescribers and practitioners to offer transdermal preparations if and when analgesic requirements are stable. It was felt important to highlight approximate opioid equivalences for transdermal patches, so that generalist prescribers can make decisions on whether a patch would be at an adequate dose, compared with oral morphine. For the subcutaneous delivery method, the review question focused on effectiveness of subcutaneous morphine compared with subcutaneous diamorphine or subcutaneous oxycodone in these patients. No evidence was found. The GDG recommended that subcutaneous opioids should be considered for patients in whom oral opioids are not suitable and whose analgesic requirements are unstable. The subcutaneous opioid BMJ Supportive & Palliative Care 2012;2:209–212. doi:10.1136/bmjspcare-2012-000313
with the lowest acquisition cost should be used, depending on a patient’s potential previous adverse effect profi le.
FIRST-LINE TREATMENT FOR BREAKTHROUGH PAIN IN PATIENTS WHO CAN TAKE ORAL OPIOIDS The aim of this topic was to determine the most effective strong opioid treatment for breakthrough pain. No randomised controlled trial (RCT) evidence was found comparing immediate-release morphine with immediate-release oxycodone. Based on clinical experience, the GDG agreed that oxycodone and morphine have very similar efficacies and side-effect profi les when used to manage breakthrough pain. However, morphine is less expensive than oxycodone and, therefore, the GDG recommended morphine for the first-line management of breakthrough pain. For the comparison of immediate-release morphine with fast-acting fentanyls, evidence was reported for intranasal fentanyl compared with immediate-release morphine, and for transmucosal fentanyl compared with immediate-release morphine. This evidence related to breakthrough cancer pain. The GDG was aware that the available literature on non-cancer-related breakthrough pain is consistent with results from the cancer population and, therefore, the GDG agreed it was appropriate to extrapolate this evidence to the wider population. No evidence was found comparing sublingual and buccal fentanyl with immediate-release morphine. The overall quality of the evidence across each of these interventions ranged from low to moderate as assessed by Grading of Recommendations Assessment Development and Evaluation Working Group (GRADE). Pain was the only outcome reported from the available evidence. No evidence was found for opioid side effects, adverse events, health-related quality of life or the percentage of patients switching to a different opioid. Because the patients included in these trials were already on other opioids, it was difficult to attribute side effects to the opioids given for breakthrough pain. Evidence reported in both systematic reviews and one RCT suggested that intranasal fentanyl was associated with superior pain relief at particular time points compared with immediate-release morphine. Although this difference was statistically significant, differences were reported at only two out of six time points. At 10 min, 52.4% of patients taking fentanyl had responded, compared with 45% of patients taking morphine. At 15 min, 75.5% of patients taking fentanyl had responded, compared with 69.3% of patients taking morphine. Given the high numbers of patients responding to morphine in these trials, the GDG did not think that these differences in pain relief from this single, moderate quality trial were clinically relevant. The GDG was also aware of the relatively small population size in each of the included studies. 211
Downloaded from http://spcare.bmj.com/ on September 22, 2015 - Published by group.bmj.com
Feature No formal cost-effectiveness analysis was conducted for this question, and a systematic review of the economic literature yielded no relevant data. The cost of treating an average breakthrough event was calculated, as shown in table 3. For the purpose of the costing exercise, it is assumed that the dose of the immediate-release preparations is equal to one-sixth of the regular daily dose. The GDG noted that fast-acting fentanyls (especially those which also require a spray canister) are considerably more expensive than immediate-release morphine, and there is no direct dose correlation with background opioid; median doses vary between trials. The GDG was satisfied that there was limited evidence to suggest that fentanyl is more clinically effective than immediate-release morphine (and immediate-release oxycodone) for the management of breakthrough pain. However, it felt the cost impact of recommending fentanyl over immediate-release morphine or oxycodone would be considerable and, therefore, could not be justified. Therefore, the GDG agreed to recommend that fast-acting fentanyls are not offered to patients commencing fi rst-line opioids, who are able to take oral opioid.
driving. The GDG recommended that this should be discussed with the individual patient.
MANAGEMENT OF SIDE EFFECTS Constipation
Contributors All authors contributed to the conception and drafting of this article and revising it critically. They have all approved this version. MB and MT are guarantors. Acknowledgements This work was undertaken by The National Collaborating Centre for Cancer which received funding from the National Institute for Health and Clinical Excellence. The views expressed in this publication are those of the authors and not necessarily those of the Institute. The members of the NICE Guideline Development Group were Damien Longson (chair), Michael Bennett, Margaret Gibbs, Natalie Laine, Catherine Piggin, Joy Ross, Lindsay Smith, Catherine Stannard, Anna-Marie Stevens and Mark Taubert. Competing interests MT, MB and JR were members of the NICE Guideline Development Group (GDG) tasked with writing NICE Guideline CG140. The National Collaborating Centre for Cancer was commissioned and funded by the National Institute for Health and Clinical Excellence to write this summary; MB has received honorariums for lectures from Cephalon and Grünenthal in the past three years but not during the period when the guideline was being developed; there were no other relationships or activities that could appear to have influenced the submitted work. Provenance and peer review Not commissioned; internally peer reviewed. Correction notice This article has been corrected since it was published Online First. The following sections have been updated for grammatical purposes: ‘The National Institute for Health and Clinical Excellence (NICE) issued guideline in May 2012,’ now reads ‘The National Institute for Health and Clinical Excellence (NICE) issued guideline CG140 in May 2012,’; ‘While NICE guideline would not usually recommend doses,’ now reads ‘While NICE guidelines would not usually recommend doses,’; and the phrase ‘to give inexperienced practitioners faced with a prescribing decision clearer guideline.’ now reads ‘to give inexperienced practitioners faced with a prescribing decision clearer guidance.’
The GDG considered constipation to be a side effect that affects nearly all patients receiving strong opioids. It therefore agreed that the best treatment strategy should be to offer regular laxatives at the same time as starting opioids. Laxatives should then be titrated and optimised before an opioid switch for constipation is considered. The GDG felt it important that patients be informed that treatment for constipation can take time to work, and that adherence is key to avoiding difficulties.
Nausea The GDG noted that nausea, as a side effect of opioid treatment, tends to occur at the start or when a dose is increased, but is usually transient. However, there was insufficient evidence to recommend that a regular antiemetic be prescribed in all patients when opioids are initiated. If nausea persists, antiemetic treatment should be considered, and there was some discussion as to delays that can occur for patients in the community setting who need to access adjuvant medications. For those patients where antiemetic regimens had been tried unsuccessfully, an opioid switch can be considered. A research recommendation was agreed to explore this further: ‘Is prophylactic prescription of antiemetic treatment or the availability of antiemetic treatment at the patient’s home more effective in reducing nausea than the availability of prescription on request for patients starting opioids?’
Drowsiness The GDG noted that despite a lack of available evidence, recommendations were required on managing drowsiness in patients who are started on opioids for advanced and progressive disease. The GDG agreed that patients should be forewarned of this side effect, and while this may be transient, persistent symptoms require opioid switching. Dose reduction if pain is responding, or opioid switching, were both seen as appropriate management strategies when and where central side effects were persistent, and/ or severe and specialist palliative care advice should be sought. The GDG agreed that on starting opioids, and when doses are increased, patients may have impaired concentration which could affect their ability to undertake manual tasks such as 212
SUMMARY This guideline is the fi rst opioid guideline to include a formal costeffectiveness analysis. As such, the emphasis is different from the recent guideline from the European Association for Palliative Care.6 The clear recommendation is that oral morphine, rather than oral oxycodone or transdermal fentanyl/buprenorphine, be used first-line in palliative care patients requiring strong opioids for pain control. Improving dialogue with patients and carers to discuss their concerns, and advising them regarding dose titration and side effects is also paramount, and will be a challenge to take forward. A NICE electronic audit tool has been developed in parallel with this guideline, as a suggested way to help with implementing the recommendations in various settings.7 Specialist palliative care providers need to support their generalist colleagues in taking these steps, and must be available to give additional advice for more complex patients, or for those who fail to respond to a first-line opioid strategy.
REFERENCES 1. 2. 3.
4. 5.
6.
7.
8.
National Institute for Health and Clinical Excellence (NICE) Opioids in palliative care CG140 May 2012 http://www.nice.org.uk/CG140 (last accessed 14 Jul 2012) National Institute for Health and Clinical Excellence (NICE) Guidelines Manual http://www.nice.org.uk/guidelinesmanual (accessed 27 June 2012). National Institute for Health and Clinical Excellence (NICE) Opioids in palliative care CG140 May 2012 page 14 of full guideline. http://guidance.nice.org.uk/ CG140/Guidance/pdf/English (last accessed 14/07/2012) Taubert M, Regnard C, Finlay I, et al. Update on cancer pain guidelines. J Pain Symptom Management 2010;39:e1–5. National Institute for Health and Clinical Excellence (NICE) Opioids in palliative care CG140 May 2012 page 34 of full guideline. http://guidance.nice.org.uk/ CG140/Guidance/pdf/English (last accessed 14 Jul 2012) Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology 2012;13:e58–68. National Institute for Health and Clinical Excellence (NICE) Opioids in palliative Care CG 140 May 2012 Electronic Audit Tool http://guidance.nice.org.uk/CG140/ ElectronicAudit/xls/English (accessed 6 June 2012). National Institute for Health and Clinical Excellence (NICE) Briefing Paper for the Methods Working Party on the Cost Effectiveness Threshold 2007 http://www.nice.org.uk/media/4A6/41/ CostEffectivenessThresholdFinalPaperTabledAtWPMeeting5Sep3907KT.pdf (accessed 28 May 2012).
BMJ Supportive & Palliative Care 2012;2:209–212. doi:10.1136/bmjspcare-2012-000313
Downloaded from http://spcare.bmj.com/ on September 22, 2015 - Published by group.bmj.com
Opioids in palliative care: is the new NICE guideline relevant to specialist palliative care providers? Mark Taubert, Joy R Ross, Matthew Prettyjohns, Mia Schmidt-Hansen and Michael I Bennett BMJ Support Palliat Care 2012 2: 209-212 originally published online July 30, 2012
doi: 10.1136/bmjspcare-2012-000313 Updated information and services can be found at: http://spcare.bmj.com/content/2/3/209
These include:
References Email alerting service
This article cites 2 articles, 0 of which you can access for free at: http://spcare.bmj.com/content/2/3/209#BIBL Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.
Notes
To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions To order reprints go to: http://journals.bmj.com/cgi/reprintform To subscribe to BMJ go to: http://group.bmj.com/subscribe/
Feature
Opioids in palliative care: is the new NICE guideline relevant to specialist palliative care providers? Mark Taubert,1–3 Joy R Ross,4,5 Matthew Prettyjohns,6 Mia Schmidt-Hansen,6 Michael I Bennett7 1Department
of Palliative Medicine, Marie Curie Hospice Penarth, Penarth, UK 2University Hospital Llandough, Penarth, UK 3Velindre Hospital NHS Trust, Cardiff, UK 4 Department of Palliative Medicine, Royal Marsden NHS Foundation Trust, London, UK 5NHLI, Imperial College, London, UK 6National Collaborating Centre for Cancer, Cardiff CF10 3AF, UK 7Leeds Institute of Life Sciences, Leeds University, Leeds, UK Correspondence to Dr Mark Taubert, Department of Palliative Medicine, Marie Curie Hospice Penarth, Bridgeman Road, Penarth, Cardiff CF64 3YR, UK; [email protected] Received 29 June 2012 Accepted 29 June 2012 Published Online First 30 July 2012
INTRODUCTION The National Institute for Health and Clinical Excellence (NICE) issued guideline CG140 in May 2012, for professionals commencing strong opioids in adult palliative care patients.1 Although this guideline is for non-specialist professionals who initiate opioid treatment (eg, general practitioners and generalist hospital doctors), the implications for those working in specialist palliative care settings will be significant. It is important that NICE guidelines should facilitate and consolidate the ongoing dialogue between generalists and specialists in palliative care. Here, we summarise the recommendations to highlight areas that are of particular importance to specialist palliative care providers.
standard baseline of care (table 1). While the prescriber is responsible for ensuring that this patient– professional dialogue occurs, it may be the case that other healthcare professionals (nurses, pharmacists) will engage and/or expand on these conversations. Given the limited research to date in this area, a research recommendation was agreed upon to explore this further: What are the most clinically effective and costeffective methods of addressing patient and carer concerns about strong opioids, including anticipating and managing adverse effects and engaging patients in prescribing decisions? (Research Recommendation B13).
STARTING STRONG OPIOIDS BACKGROUND Development of this guideline followed the NICE process for short clinical guideline development. 2 Recommendations within the guideline were made after systematic reviews had been conducted to consider the best available evidence. Where minimal evidence was available, the Guideline Development Group’s experience and opinion of what constitutes good practice was debated, considered and summarised. The guideline takes effect at the point in time when a palliative care patient has moderate to severe pain, which necessitates commencing strong opioid analgesia. The guideline does not cover the last days of life, nor does it go further into recommendations for second-line approaches for pain control. A number of key areas are addressed: communication, starting strong opioids (fi rst-line treatment options, titrating the dose, maintenance phase and what to do when oral opioids are not suitable), management of breakthrough pain, and management of side effects (constipation, nausea and drowsiness). These are summarised in table 1.
COMMUNICATION The Guideline Development Group (GDG) highlighted that communication with patients starting opioids is often inadequate and should incorporate the salient aspects of what opioid therapy entails. GDG members working in both community and hospital settings were aware that communication gaps exist when this intervention (initiation of opioids) is made. Exploring patients’ concerns when discussing an opioid for the fi rst time has a significant impact on whether or not a patient actually takes their medication as prescribed. The GDG recommended a minimum level of information that should be covered to constitute a good BMJ Supportive & Palliative Care 2012;2:209–212. doi:10.1136/bmjspcare-2012-000313
Titrating the dose: the guideline is focused on the decision to commence strong opioids. This decision might be made by a general practitioner reviewing a community palliative care patient or a hospital doctor seeing an inpatient on a ward. The GDG agreed that offering patients a choice of immediate- or sustained-release formulations would be likely to improve adherence because patients would be able to choose the formulation that was most acceptable to them. Based on their clinical experience, the GDG recommended that all patients are given rescue doses of an immediate-release opioid to be taken as required, in order to minimise pain in the initial titration phase. Wide ranges of doses are used in the initiation of opioids by hospital and community practitioners, and the guideline literature varies considerably.4 While NICE guidelines would not usually recommend doses, feedback from the consultation process and the GDG was that this was an important safety consideration. It was therefore decided that a safe starting dose of morphine should be suggested, to give inexperienced practitioners faced with a prescribing decision clearer guidance. The GDG recommended a starting dose of regular oral daily opioid (which can be prescribed as a regular immediate-release or sustained-release preparation) of 20–30 mg of morphine over 24 h, plus additional rescue doses of immediate-release oral morphine at a dose of 5 mg. It was also agreed that in both inpatient and community settings, regular and frequent review was necessary in the titration phase to allow appropriate dose escalation to achieve analgesia and to monitor side effects. For those patients with renal or hepatic impairment, specialist advice from a palliative care team should be sought, due to the challenges these particular clinical situations can pose when prescribing opioids. 209
Downloaded from http://spcare.bmj.com/ on September 22, 2015 - Published by group.bmj.com
Feature Table 1
Summary of NICE recommendations for opioids in palliative care
Communication 1.1.1 When offering pain treatment with strong opioids to a patient with advanced and progressive disease, ask them about concerns such as: addiction, tolerance, side effects, fears that treatment implies the final stages of life. 1.1.2 Provide verbal and written information on strong opioid treatment to patients and carers, including the following: when and why strong opioids are used to treat pain; how effective they are likely to be; taking strong opioids for background and breakthrough pain; addressing how, when and how often to take strong opioids, and how long pain relief should last; side effects and signs of toxicity; safe storage; follow-up and further prescribing; information on who to contact out of hours, particularly during initiation of treatment. 1.1.3 Offer patients access to frequent review of pain control and side effects. Starting strong opioids – titrating the dose 1.1.4 When starting treatment with strong opioids, offer patients with advanced and progressive disease regular oral sustained-release or oral immediate-release morphine (depending on patient preference), with rescue doses of oral immediate-release morphine for breakthrough pain. 1.1.5 For patients with no renal or hepatic comorbidities, offer a typical total daily starting dose schedule of 20–30 mg of oral morphine (for example, 10–15 mg oral sustained-release morphine twice daily), plus 5 mg oral immediate-release morphine for rescue doses during the titration phase. 1.1.6 Adjust the dose until a good balance exists between acceptable pain control and side effects. If this balance is not reached after a few dose adjustments, seek specialist advice. Offer patients frequent review, particularly in the titration phase. 1.1.7 Seek specialist advice before prescribing strong opioids for patients with moderate to severe renal or hepatic impairment. First-line maintenance treatment 1.1.8 Offer oral sustained-release morphine as first-line maintenance treatment to patients with advanced and progressive disease who require strong opioids. 1.1.9 Do not routinely offer transdermal patch formulations as first-line maintenance treatment to patients in whom oral opioids are suitable. 1.1.10 If pain remains inadequately controlled despite optimising first-line maintenance treatment, review analgesic strategy and consider seeking specialist advice. First-line treatment if oral opioids are not suitable – transdermal patches 1.1.11 Consider initiating transdermal patches with the lowest acquisition cost for patients in whom oral opioids are not suitable and analgesic requirements are stable, supported by specialist advice where needed. 1.1.12 Use caution when calculating opioid equivalence for transdermal patches: a transdermal fentanyl 12 µg patch equates to approximately 45 mg oral morphine daily. A transdermal buprenorphine 20 µg patch equates to approximately 30 mg oral morphine daily. First-line treatment if oral opioids are not suitable – subcutaneous delivery 1.1.13 Consider initiating subcutaneous opioids with the lowest acquisition cost for patients in whom oral opioids are not suitable and analgesic requirements are unstable, supported by specialist advice where needed. First-line treatment for breakthrough pain in patients who can take oral opioids 1.1.14 Offer oral immediate-release morphine for the first-line rescue medication of breakthrough pain in patients on maintenance oral morphine treatment. 1.1.15 Do not offer fast-acting fentanyl as first-line rescue medication. 1.1.16 If pain remains inadequately controlled despite optimising treatment, consider seeking specialist advice. Management of constipation 1.1.17 Inform patients that constipation affects nearly all patients receiving strong opioid treatment. 1.1.18 Prescribe laxative treatment (to be taken regularly at an effective dose) for all patients initiating strong opioids. 1.1.19 Inform patients that treatment for constipation takes time to work, and adherence is important. 1.1.20 Optimise laxative treatment for managing constipation before considering switching strong opioids. Management of nausea 1.1.21 Advise patients that nausea may occur when starting strong opioid treatment or at dose increase, but that it is likely to be transient. 1.1.22 If nausea persists, prescribe and optimise antiemetic treatment before considering switching strong opioids. Management of drowsiness 1.1.23 Advise patients that mild drowsiness or impaired concentration may occur when starting strong opioid treatment or at dose increase, but that it is often transient. Warn patients that impaired concentration may affect their ability to drive and undertake other manual tasks. 1.1.24 In patients with either persistent or moderate to severe central nervous system side effects: consider dose reduction if pain is controlled, or consider switching opioids if pain is not controlled. 1.1.25 If side effects remain uncontrolled despite optimising treatment, consider seeking specialist advice.
FIRST-LINE MAINTENANCE TREATMENT A literature search and a health economic modelling exercise 5 were conducted to establish the most effective fi rst-line maintenance treatment for patients with advanced and progressive disease who are able to take oral opioids. The GDG noted that uncertainty exists over the choice of a strong opioid for the maintenance treatment of background pain. The prescription of transdermal fentanyl and buprenorphine preparations has increased in both hospital and community settings, and the GDG decided that this warranted further consideration. Based on the available evidence, the GDG noted that morphine is an effective and inexpensive opioid analgesic. Although its use may result in a small increase in gastrointestinal side effects compared with transdermal patches, the 210
GDG agreed that this could be managed by using adjunctive treatment. More costly preparations would need to be justified by evidence of superior efficacy or a much lower sideeffect burden. Studies comparing the effectiveness of fentanyl, buprenorphine and oxycodone with morphine were of poor quality and did not demonstrate superiority over morphine. Health economic modelling showed that the benefit potentially conferred by fentanyl in reducing gastrointestinal side effects was not shown to be cost effective (ICER £107 532 per quality adjusted life year (QALY) gained at 1 month, see table 2 for explanation of abbreviations. The threshold that NICE sets for QALYs is £20 000 per QALY). It was agreed that oral sustained-release morphine should be recommended as fi rst-line maintenance treatment for patients BMJ Supportive & Palliative Care 2012;2:209–212. doi:10.1136/bmjspcare-2012-000313
Downloaded from http://spcare.bmj.com/ on September 22, 2015 - Published by group.bmj.com
Feature Table 2
Definitions of CEA, ICER and QALY8
NICE is charged with considering both the effectiveness and cost effectiveness of treatments, and then with making recommendations as to their provision within the National Health Service (NHS). QALY: the QALY is based on the number of years of life that may be added by an intervention. Each year in ‘full or perfect health’ is assigned the value of 1.0, and this can go down to a value of 0.0 for death. If the extra years cannot be lived in full health, for instance, if a patient were to be restricted in their mobility or in severe pain, then the extra life years are given a value between 0 and 1 to take this debility into account. CEA: assesses two or more alternative courses of action in terms of their costs and benefi ts. The comparison is summarised using the expected ICER. ICER: this is a measure of the additional cost per additional unit of health gain produced by one intervention compared with another. The Institute’s preferred form of cost effectiveness analysis uses the QALY to describe the outcome of each intervention. By extension, the Institute’s preferred form of ICER is the cost per QALY gained. The cost-effectiveness threshold is often referred to as society’s willingness to pay for an additional unit of health gain (QALY); that is, if the ICER for a specific intervention is less than the cost-effectiveness threshold, then society, or its agents, will be willing to fund it, and conversely, if the ICER is greater than the threshold, society will not be willing to fund it. CEA, cost-effectiveness analysis; ICER, incremental cost-effectiveness ratio; NICE, National Institute for Health and Clinical Excellence; QALY, quality adjusted life year.
Table 3 Therapy
Costs of breakthrough pain medication Average price per Regular dose Breakthrough dose (a) breakthrough event (£)
Morphine 60 mg Oxycodone 30 mg Fentanyl 25 µg/h (b) Intranasal (c) Sublingual Buccal Buccal
10 mg 5 mg
0.09 0.20
100 µg 100 µg 100 µg (d) 200 µg (e)
4.88 4.99 4.99 5.85
a Typically one-sixth of regular daily dose. b Patch dose. c Average of instanyl (100 µg) and pecfent (100 µg). d Initial dose of effentora (100 µg). e Initial doses of actiq (200 µg).
with advanced disease, and that transdermal patch formulations should not be used routinely as fi rst-line treatment. If pain control remains inadequate despite titrating and optimising oral sustained-release morphine, then generalist prescribers should consider seeking specialist palliative care advice.
FIRST-LINE TREATMENT IF ORAL OPIOIDS ARE NOT SUITABLE – TRANSDERMAL PATCHES AND SUBCUTANEOUS DELIVERY The GDG addressed the question of what happens to patients who cannot swallow oral medication, or have impaired absorption from the gastrointestinal tract (eg, due to nausea and vomiting). Recommendations were made on the use of transdermal and subcutaneous routes of administration in this setting. The evidence for effectiveness of transdermal patches was low quality, and defi nitive recommendations on which transdermal patch to offer patients could not be made. The GDG recognised that most patients in this category would have complex medical needs requiring specialist advice, however, there needed to be flexibility for experienced generalist prescribers and practitioners to offer transdermal preparations if and when analgesic requirements are stable. It was felt important to highlight approximate opioid equivalences for transdermal patches, so that generalist prescribers can make decisions on whether a patch would be at an adequate dose, compared with oral morphine. For the subcutaneous delivery method, the review question focused on effectiveness of subcutaneous morphine compared with subcutaneous diamorphine or subcutaneous oxycodone in these patients. No evidence was found. The GDG recommended that subcutaneous opioids should be considered for patients in whom oral opioids are not suitable and whose analgesic requirements are unstable. The subcutaneous opioid BMJ Supportive & Palliative Care 2012;2:209–212. doi:10.1136/bmjspcare-2012-000313
with the lowest acquisition cost should be used, depending on a patient’s potential previous adverse effect profi le.
FIRST-LINE TREATMENT FOR BREAKTHROUGH PAIN IN PATIENTS WHO CAN TAKE ORAL OPIOIDS The aim of this topic was to determine the most effective strong opioid treatment for breakthrough pain. No randomised controlled trial (RCT) evidence was found comparing immediate-release morphine with immediate-release oxycodone. Based on clinical experience, the GDG agreed that oxycodone and morphine have very similar efficacies and side-effect profi les when used to manage breakthrough pain. However, morphine is less expensive than oxycodone and, therefore, the GDG recommended morphine for the first-line management of breakthrough pain. For the comparison of immediate-release morphine with fast-acting fentanyls, evidence was reported for intranasal fentanyl compared with immediate-release morphine, and for transmucosal fentanyl compared with immediate-release morphine. This evidence related to breakthrough cancer pain. The GDG was aware that the available literature on non-cancer-related breakthrough pain is consistent with results from the cancer population and, therefore, the GDG agreed it was appropriate to extrapolate this evidence to the wider population. No evidence was found comparing sublingual and buccal fentanyl with immediate-release morphine. The overall quality of the evidence across each of these interventions ranged from low to moderate as assessed by Grading of Recommendations Assessment Development and Evaluation Working Group (GRADE). Pain was the only outcome reported from the available evidence. No evidence was found for opioid side effects, adverse events, health-related quality of life or the percentage of patients switching to a different opioid. Because the patients included in these trials were already on other opioids, it was difficult to attribute side effects to the opioids given for breakthrough pain. Evidence reported in both systematic reviews and one RCT suggested that intranasal fentanyl was associated with superior pain relief at particular time points compared with immediate-release morphine. Although this difference was statistically significant, differences were reported at only two out of six time points. At 10 min, 52.4% of patients taking fentanyl had responded, compared with 45% of patients taking morphine. At 15 min, 75.5% of patients taking fentanyl had responded, compared with 69.3% of patients taking morphine. Given the high numbers of patients responding to morphine in these trials, the GDG did not think that these differences in pain relief from this single, moderate quality trial were clinically relevant. The GDG was also aware of the relatively small population size in each of the included studies. 211
Downloaded from http://spcare.bmj.com/ on September 22, 2015 - Published by group.bmj.com
Feature No formal cost-effectiveness analysis was conducted for this question, and a systematic review of the economic literature yielded no relevant data. The cost of treating an average breakthrough event was calculated, as shown in table 3. For the purpose of the costing exercise, it is assumed that the dose of the immediate-release preparations is equal to one-sixth of the regular daily dose. The GDG noted that fast-acting fentanyls (especially those which also require a spray canister) are considerably more expensive than immediate-release morphine, and there is no direct dose correlation with background opioid; median doses vary between trials. The GDG was satisfied that there was limited evidence to suggest that fentanyl is more clinically effective than immediate-release morphine (and immediate-release oxycodone) for the management of breakthrough pain. However, it felt the cost impact of recommending fentanyl over immediate-release morphine or oxycodone would be considerable and, therefore, could not be justified. Therefore, the GDG agreed to recommend that fast-acting fentanyls are not offered to patients commencing fi rst-line opioids, who are able to take oral opioid.
driving. The GDG recommended that this should be discussed with the individual patient.
MANAGEMENT OF SIDE EFFECTS Constipation
Contributors All authors contributed to the conception and drafting of this article and revising it critically. They have all approved this version. MB and MT are guarantors. Acknowledgements This work was undertaken by The National Collaborating Centre for Cancer which received funding from the National Institute for Health and Clinical Excellence. The views expressed in this publication are those of the authors and not necessarily those of the Institute. The members of the NICE Guideline Development Group were Damien Longson (chair), Michael Bennett, Margaret Gibbs, Natalie Laine, Catherine Piggin, Joy Ross, Lindsay Smith, Catherine Stannard, Anna-Marie Stevens and Mark Taubert. Competing interests MT, MB and JR were members of the NICE Guideline Development Group (GDG) tasked with writing NICE Guideline CG140. The National Collaborating Centre for Cancer was commissioned and funded by the National Institute for Health and Clinical Excellence to write this summary; MB has received honorariums for lectures from Cephalon and Grünenthal in the past three years but not during the period when the guideline was being developed; there were no other relationships or activities that could appear to have influenced the submitted work. Provenance and peer review Not commissioned; internally peer reviewed. Correction notice This article has been corrected since it was published Online First. The following sections have been updated for grammatical purposes: ‘The National Institute for Health and Clinical Excellence (NICE) issued guideline in May 2012,’ now reads ‘The National Institute for Health and Clinical Excellence (NICE) issued guideline CG140 in May 2012,’; ‘While NICE guideline would not usually recommend doses,’ now reads ‘While NICE guidelines would not usually recommend doses,’; and the phrase ‘to give inexperienced practitioners faced with a prescribing decision clearer guideline.’ now reads ‘to give inexperienced practitioners faced with a prescribing decision clearer guidance.’
The GDG considered constipation to be a side effect that affects nearly all patients receiving strong opioids. It therefore agreed that the best treatment strategy should be to offer regular laxatives at the same time as starting opioids. Laxatives should then be titrated and optimised before an opioid switch for constipation is considered. The GDG felt it important that patients be informed that treatment for constipation can take time to work, and that adherence is key to avoiding difficulties.
Nausea The GDG noted that nausea, as a side effect of opioid treatment, tends to occur at the start or when a dose is increased, but is usually transient. However, there was insufficient evidence to recommend that a regular antiemetic be prescribed in all patients when opioids are initiated. If nausea persists, antiemetic treatment should be considered, and there was some discussion as to delays that can occur for patients in the community setting who need to access adjuvant medications. For those patients where antiemetic regimens had been tried unsuccessfully, an opioid switch can be considered. A research recommendation was agreed to explore this further: ‘Is prophylactic prescription of antiemetic treatment or the availability of antiemetic treatment at the patient’s home more effective in reducing nausea than the availability of prescription on request for patients starting opioids?’
Drowsiness The GDG noted that despite a lack of available evidence, recommendations were required on managing drowsiness in patients who are started on opioids for advanced and progressive disease. The GDG agreed that patients should be forewarned of this side effect, and while this may be transient, persistent symptoms require opioid switching. Dose reduction if pain is responding, or opioid switching, were both seen as appropriate management strategies when and where central side effects were persistent, and/ or severe and specialist palliative care advice should be sought. The GDG agreed that on starting opioids, and when doses are increased, patients may have impaired concentration which could affect their ability to undertake manual tasks such as 212
SUMMARY This guideline is the fi rst opioid guideline to include a formal costeffectiveness analysis. As such, the emphasis is different from the recent guideline from the European Association for Palliative Care.6 The clear recommendation is that oral morphine, rather than oral oxycodone or transdermal fentanyl/buprenorphine, be used first-line in palliative care patients requiring strong opioids for pain control. Improving dialogue with patients and carers to discuss their concerns, and advising them regarding dose titration and side effects is also paramount, and will be a challenge to take forward. A NICE electronic audit tool has been developed in parallel with this guideline, as a suggested way to help with implementing the recommendations in various settings.7 Specialist palliative care providers need to support their generalist colleagues in taking these steps, and must be available to give additional advice for more complex patients, or for those who fail to respond to a first-line opioid strategy.
REFERENCES 1. 2. 3.
4. 5.
6.
7.
8.
National Institute for Health and Clinical Excellence (NICE) Opioids in palliative care CG140 May 2012 http://www.nice.org.uk/CG140 (last accessed 14 Jul 2012) National Institute for Health and Clinical Excellence (NICE) Guidelines Manual http://www.nice.org.uk/guidelinesmanual (accessed 27 June 2012). National Institute for Health and Clinical Excellence (NICE) Opioids in palliative care CG140 May 2012 page 14 of full guideline. http://guidance.nice.org.uk/ CG140/Guidance/pdf/English (last accessed 14/07/2012) Taubert M, Regnard C, Finlay I, et al. Update on cancer pain guidelines. J Pain Symptom Management 2010;39:e1–5. National Institute for Health and Clinical Excellence (NICE) Opioids in palliative care CG140 May 2012 page 34 of full guideline. http://guidance.nice.org.uk/ CG140/Guidance/pdf/English (last accessed 14 Jul 2012) Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology 2012;13:e58–68. National Institute for Health and Clinical Excellence (NICE) Opioids in palliative Care CG 140 May 2012 Electronic Audit Tool http://guidance.nice.org.uk/CG140/ ElectronicAudit/xls/English (accessed 6 June 2012). National Institute for Health and Clinical Excellence (NICE) Briefing Paper for the Methods Working Party on the Cost Effectiveness Threshold 2007 http://www.nice.org.uk/media/4A6/41/ CostEffectivenessThresholdFinalPaperTabledAtWPMeeting5Sep3907KT.pdf (accessed 28 May 2012).
BMJ Supportive & Palliative Care 2012;2:209–212. doi:10.1136/bmjspcare-2012-000313
Downloaded from http://spcare.bmj.com/ on September 22, 2015 - Published by group.bmj.com
Opioids in palliative care: is the new NICE guideline relevant to specialist palliative care providers? Mark Taubert, Joy R Ross, Matthew Prettyjohns, Mia Schmidt-Hansen and Michael I Bennett BMJ Support Palliat Care 2012 2: 209-212 originally published online July 30, 2012
doi: 10.1136/bmjspcare-2012-000313 Updated information and services can be found at: http://spcare.bmj.com/content/2/3/209
These include:
References Email alerting service
This article cites 2 articles, 0 of which you can access for free at: http://spcare.bmj.com/content/2/3/209#BIBL Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.
Notes
To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions To order reprints go to: http://journals.bmj.com/cgi/reprintform To subscribe to BMJ go to: http://group.bmj.com/subscribe/
